Correction

Correction: Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study

Yumiko Tatsukawa1,2, Masataka Tsuge1,2,3, Yoshiiku Kawakami1,2, Yuichi Hiyama1, Eisuke Murakami1,2, Mio Kurihara1,2, Motonobu Nomura1,2, Ken Tsushima1,2, Takuro Uchida1,2, Takashi Nakahara1,2, Daiki Miki1,2,4, Tomokazu Kawaoa1,2, Hiromi Abe-Chayama1,2, Michio Imamura1,2, Hiroshi Aikata1,2, Hidenori Ochi1,2,4, C Nelson Hayes1,2, Hiroiku Kawakami5, Kazuaki Chayama1,2,*

1Department of Gastroenterology and Metabolism, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan
2Research Center for Hepatology and Gastroenterology, Hiroshima University, Hiroshima, Japan
3Natural Science Center for Basic Research and Development, Hiroshima University, Hiroshima, Japan
4Laboratory for Digestive Diseases, Center for Genomic Medicine, The Institute of Physical and Chemical Research (RIKEN), Hiroshima, Japan
5Kawakami Clinic, Hiroshima, Japan

*Corresponding author e-mail: chayama@hiroshima-u.ac.jp

The publisher would like to report an error that appeared in a published article [1]. The author Yuichi Hiyama was omitted from the original author list. This has been corrected as of 11 January 2019. The authors apologize for this error.

Reference